Close Menu

Personalis

Personalis said that it plans to form a wholly owned subsidiary in Shanghai, including a laboratory for local customers to use its ImmunoID NeXT platform.

The companies are applying Personalis' technology to explore immune response to genetic therapeutics in Sarepta's pipeline.

The company said Q1 revenue growth was driven by an increase in testing volume and analytical services provided to the US Department of Veterans Affairs.

The company is now marketing what it calls its Pharma Research Solutions, including a more flexible array of molecular analyses than its existing NeXT platform.

The firms are pairing Personalis' comprehensive cancer genomics technology with Indivumed's multiomic database, hoping to improve the insights gleaned from banked samples.

The company said Q4 revenue growth was driven by an increase in testing volume and analytical services provided to the US Department of Veterans Affairs.

Extending a prior agreement with the drugmaker, Personalis will use its DNA/RNA platform to identify both predictive biomarkers and resistance mechanisms.

The partners plan to employ Personalis' ImmunoID NeXT platform to investigate biomarkers of response and mechanisms of resistance to cancer therapies.

The company is hoping that the comprehensive solution will help bring on more pharma customers and offer extended opportunities for current users.

Pages

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.